prostate cancer

AstraZeneca's prostate drug Truqap wins FDA panel backing (7-1 vote) for PTEN-deficient tumors, but breast cancer candidate camizestrant rejected despite superior efficacy data.

Telix's next-gen prostate cancer therapy shows reduced organ toxicity in Phase 2 trial, expanding into earlier-stage disease applications with expanded clinical potential.

Telix Pharmaceuticals hosts webinar April 30 discussing next-gen PSMA cancer therapy pipeline, featuring OPTIMAL-PSMA2 trial data on TLX597-Tx candidate.

Vir Biotechnology CEO Marianne De Backer sold 72,559 shares worth $664,350, representing 6.76% of holdings. Sale aligns with historical patterns amid company's positive momentum.

ORIC Pharmaceuticals surged then crashed 25% after-hours despite publishing positive Phase 1b trial results for cancer therapy candidate rinzimetostat, highlighting biotech market skepticism.

Radiopharm Theranostics doses first patient in Phase 1 trial of RAD 402, a targeted radioimmune therapy for advanced prostate cancer, with data expected H2 2026.

Pfizer shares rise on Phase 3 prostate cancer trial win and Phase 2 breast cancer success, validating its oncology pipeline and signaling near-term regulatory catalysts.

MDxHealth's genomic prostate cancer test demonstrates strong predictive performance across treatment settings, supporting path toward randomized clinical trial validation.

Telix Pharmaceuticals' TLX591-Tx meets Phase 3 safety objectives in prostate cancer trial, advancing toward U.S. expansion with FDA.

Kyntra Bio will report fourth quarter and full year 2025 financial results on March 16, 2026, as the biopharmaceutical company advances its oncology and rare disease pipeline.

Telix Pharmaceuticals announces March 2026 webinar on PSMA-PET/CT imaging innovations, featuring leading oncology experts discussing prostate cancer detection advances.

Telix Pharmaceuticals expands its nuclear medicine presence with approved cancer-targeting drugs and 56% revenue growth, positioning itself as a key player in oncology diagnostics and therapeutics.

PYLARIFY becomes first radiodiagnostic to exceed $1 billion in annual sales with 24% growth, as PSMA-targeted prostate cancer treatments gain significant market momentum.

Candel Therapeutics raises $100M via public share offering to fund commercialization of its prostate cancer gene therapy and ongoing lung cancer clinical trials.

Candel Therapeutics plans $100M stock offering to fund cancer treatment pipeline development, particularly for prostate and lung cancer therapies.